Clearside Biomedical (CLSD) Receives a Buy from Wedbush

Wedbush analyst Liana Moussatos reiterated a Buy rating on Clearside Biomedical (CLSD) today and set a price target of $4. The company’s shares opened today at $2.50, close to its 52-week low of $2.05.

According to TipRanks.com, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -6.2% and a 37.0% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics Inc, Allena Pharmaceuticals Inc, and Catabasis Pharmaceuticals.

Currently, the analyst consensus on Clearside Biomedical is a Moderate Buy with an average price target of $16.50, representing a 560.0% upside. In a report issued on October 30, Cowen & Co. also assigned a Buy rating to the stock.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $15.33 and a one-year low of $2.05. Currently, Clearside Biomedical has an average volume of 243.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy.